SLU-PP-332
An ERRα (estrogen-related receptor alpha) agonist developed at Washington University. A next-generation exercise mimetic that enhances endurance capacity and promotes slow-twitch muscle fiber transformation through a completely different mechanism than AICAR. Activates the same transcriptional programs that endurance training induces, including mitochondrial biogenesis and oxidative metabolism genes.
Typical Dosage
Preclinical only: mouse studies used 25-50 mg/kg oral. No established human dosing protocol. Very early stage compound with no human trials conducted.
Administration
Oral or injection (preclinical only)
Mechanism of Action
SLU-PP-332 is a small molecule agonist of estrogen-related receptor alpha (ERRα), one of three orphan nuclear receptors in the ERR family. Despite its name, ERRα does not bind estrogen — it was named for its structural similarity to estrogen receptors. ERRα is constitutively active and functions as a master transcription factor for genes controlling mitochondrial biogenesis, oxidative phosphorylation, and fatty acid oxidation, particularly in metabolically active tissues like skeletal muscle, heart, and brown adipose tissue.
SLU-PP-332 enhances ERRα transcriptional activity by stabilizing its active conformation and promoting coactivator recruitment (particularly PGC-1α, which is both an ERRα target gene and an ERRα coactivator, creating a positive feed-forward loop). Activated ERRα binds to ERR response elements (ERREs) in the promoter regions of hundreds of metabolic genes, upregulating the entire oxidative metabolism gene program: mitochondrial electron transport chain subunits, fatty acid oxidation enzymes, TCA cycle enzymes, and mitochondrial transcription and replication factors.
The most striking effect in preclinical studies is the transformation of skeletal muscle fiber type composition. SLU-PP-332 treatment increases the proportion of slow-twitch (type I) and oxidative fast-twitch (type IIA) fibers while decreasing glycolytic fast-twitch (type IIB/IIX) fibers. Type I fibers are rich in mitochondria, capillaries, and myoglobin — they are the fibers that endurance athletes develop through years of training. By pharmacologically shifting this fiber type ratio, SLU-PP-332 produces endurance capacity gains similar to what would require months of aerobic training. In mouse studies published in 2023, treated animals ran significantly longer and farther on treadmill tests. This ERRα-mediated mechanism is distinct from and potentially complementary to AMPK-based exercise mimetics like AICAR, as it targets a different node in the mitochondrial biogenesis regulatory network.
Regulatory Status
Not FDA approved. Preclinical research compound. Published in 2023 by Washington University. No clinical trials. Available through research chemical suppliers.
Risks & Safety
Common: unknown (no human data). Serious: no human safety data exists, potential off-target effects of ERRα activation on estrogen-responsive tissues and metabolic pathways are completely unknown. Rare: unknown. Entirely preclinical compound. Not FDA approved.
Research Papers
No research papers indexed yet. Papers are fetched from PubMed weekly.
Related Peptides
5-Amino-1MQ
A small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme significantly overexpressed in white adipose tissue of obese individuals. Not technically a peptide but commonly sold alongside peptides in weight management protocols. Works by preserving cellular NAD+ and SAM pools, shifting fat cells from a storage to a fat-burning metabolic state.
ACE-031
A soluble activin receptor type IIB fusion protein (ActRIIB-Fc) that acts as a broad-spectrum myostatin/activin 'decoy receptor,' intercepting these muscle-growth inhibitors before they reach target tissues. Produced rapid muscle mass gains in clinical trials without exercise, but development was halted due to vascular side effects caused by inadvertent blockade of BMP-9/BMP-10 endothelial signaling.
AICAR
5-Aminoimidazole-4-carboxamide ribonucleotide — an endogenous intermediate of purine biosynthesis that activates AMP-kinase (AMPK), the cellular energy sensor triggered by exercise. Mimics the metabolic effects of endurance exercise at the cellular level, enhancing fat oxidation, glucose uptake, and mitochondrial biogenesis. Banned by WADA as a metabolic modulator after detection in professional cycling.
BPC-157
Body Protection Compound-157 — a synthetic pentadecapeptide (15 amino acids) derived from a protective protein found in human gastric juice. The most widely studied regenerative peptide, with extensive animal research demonstrating healing effects on tendons, ligaments, muscles, the gut, and multiple organ systems. Uniquely stable in gastric acid, enabling both injectable and oral administration.